Alexion, AstraZeneca Rare Disease, highlights the urgent need to elevate patients’ voices to accelerate rare disease innovation
Angelini Pharma tells Pharmafocus about the global challenge of epilepsy as well as how his company is striving to bridge the gaps in epilepsy treatment
Beckley Psytech tells Pharmafocus about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and how this field could develop in the future
Compass Pathways explores the need for new treatments in the mental health space, as well as assessing whether psychoactives could be the way forward
Pharmafocus considers the need for sustainable practices in the pharma industry, and assesses various sustainable advances that have already been made

Top news

Page 4 – AstraZeneca and Daiichi Sankyo’s BLA for datopotamab deruxtecan accepted by FDA for breast cancer treatment
Page 6 – Sanofi announces data from phase 3 LUNA 3 trial for immune
thrombocytopaenia treatment
Page 10 – Neurolentech and Kaerus Bioscience collaborate on
neurodevelopmental disorder research
Page 12 – Johnson & Johnson announces acquisition of Shockwave Medical
for $13.1bn

Our Team

Executive Director
PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
Editorial Assistants
Betsy Goodfellow

Sales Manager
Eliot Haynes
Design & Layout
Peter May
Pharmafocus is published by:
Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
ISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2024 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.